Edgewise Therapeutics

Edgewise Therapeutics develops oral medicines for people with rare and serious muscle diseases. These treatments aim to fix the underlying causes of muscle breakdown and heart conditions. The company uses a custom testing platform to build a pipeline of targeted therapies.

Targeting Rare Muscle Disorders

• Sevasemten: Oral drug candidate designed to stop contraction-induced muscle damage in patients with Becker and Duchenne muscular dystrophy.
• EDG-7500: Cardiac therapy that slows contraction velocity to help the heart relax in patients with hypertrophic cardiomyopathy.
• EDG-15400: Experimental molecule in early-stage testing for heart failure with preserved ejection fraction, a condition where the heart is too stiff.
• Discovery Platform: Proprietary system that identifies molecules by measuring how they affect the function of whole muscle extracts.

Milestones in Clinical Development

• Raised $200 million in gross proceeds through a registered direct offering closed in April 2025.
• Entered a sales agreement in May 2024 with Leerink Partners LLC for an at-the-market offering program of up to $175 million.
• Advanced sevasemten into multiple Phase 2 clinical trials, including the ongoing CANYON study for patients with Becker muscular dystrophy.
• Started a Phase 1 trial for EDG-15400 in healthy adults during the third quarter of 2025.

Specialized Muscle Biology Focus

The company focuses on the muscle as a whole organ rather than studying individual cells in isolation. This integrated approach allows scientists to identify precision medicines that regulate specific proteins found in neuromuscular and cardiac tissues.

Measuring the Financial Path

• Operating loss deepened to $54.1 million in Q1 2026, worsening 17.7% from the same period in 2025.
• Net loss reached $49.0 million in Q1 2026, a 20.1% increase in losses compared to the previous year.
• Research and development costs rose to $42.7 million in Q1 2026, up from $36.8 million in Q1 2025.
• Total cash, equivalents, and marketable securities were $499.6 million as of March 31, 2026.

Summary of Business Progress

Edgewise has evolved from a discovery-stage firm into a late-stage clinical company with multiple programs for rare diseases. Its development of specialized muscle modulators and significant cash reserves support its efforts to reach commercial readiness.